About Us

Who We Are

We are a development-stage international company ADVANCED BIORESEARCH & TECHNOLOGY (ABRT) founded in 2007 in Luxemburg.

Prehistory: A small team of biologists and medical professionals headed by Dr. Marina Shaduri and late George Tchitchinadze (the Center of Bioholography in Tbilisi, Georgia) made a discovery of a previously unknown type of bio-communication that opens new horizons in theoretical and practical Biomedicine.

Our present mission is to further explore the holography-based biological mechanisms, prove the concept and harness gained knowledge into practical products and services. We are starting with an application we have done a significant amount of work on: an easy-to-implement cancer diagnostic system. Dr. Marc Bouchoucha - a France-based medical practitioner as well as some business angel backers, recognized the great potential of their revolutionary innovation. This resulted in the reorganization of Dr. Shaduri's team under the Luxemburg-based company Advanced Bioresearch and Technology (ABRT) with the common goal of building a world-class organization to leverage the discovery and its numerous potential applications. The medical applications of new interdisciplinary science - BIOHOLOGRAPHY - have been developed since then through fully safe, experimental and clinical research on human subjects, as well as through seminars and workshops conducted in cooperation with the International Association of Bioholography Study (AIPEB, France).

ABRT has developed and implemented into everyday medical practice a new approach to the medical imaging and cancer diagnostics. A small computer-assisted device makes it possible to detect cancer through analysis of spectra emitted from the body's surface. This is a great leap forward in oncology as modern medicine does not yet have reliable, harmless and affordable tests for mass-screening purposes. Mass population screening is available for 2-3 types of cancers in developed countries. None of the conventional technologies is capable to check the entire body for any type of cancer in several minutes and at a low cost. The earlier the detection takes place, the higher the probability of survival and the lower the economic impact. Our strategic innovation can reshape the cancer detection by allowing mass screening of large populations. It will also create a new niche in the medical market.

The most difficult part of R&D is already accomplished. We greatly appreciate the contribution of numerous medical professionals and general practitioners who have helped us create a solid database of patients' recordings. Since the discovery of this new phenomenon in 2000, up to 13800 volunteers have been examined while developing and testing various modifications of the diagnostic devices.

The present version of the hardware-software system "CID" serves as a partially automated tool capable of detecting the cancerous processes of any location and at any stage of the disease development. A simple, single, fast, non-invasive, absolutely harmless and automatable test is sensitive to early stage cancers. Today we have already gained enough knowledge and experience to start open discussions, collaboration, large-scale clinical trials and commercial activity (The CID-project). Once fully automated, the diagnostic test can be used by both - general practitioners and professional oncologists - for cancer-screening, monitoring of certain health-deteriorating factors, epidemiological studies/surveillance, etc. In future regular check-ups for malignant processes will be part of routine care.

Marina Shaduri, Ph.D. >>> short CV

Marc Bouchoucha, MD/DO >>> short CV